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Introduction
The human epidermal growth factor receptor-2/neu
gene (HER-2/neu) is a proto-oncogene that is overampli-
fied and/or overexpressed in up to 30% of patients with
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SUMMARY
Objective: Accurate diagnostic assessment of human epidermal growth factor receptor-2 (HER-2) is essential
and a prerequisite for appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab
(Herceptin) to the treatment of patients with breast cancer. Immunohistochemistry (IHC) is the most widely
applicable diagnostic modality in studying HER-2 status. Fluorescence in situ hybridization (FISH) is also recog-
nized as a modality in cases with an equivocal IHC status (score, 2+). Some authors claimed that FISH alone is
sufficient. The aim of this study was to correlate the test results of IHC and FISH for HER-2 gene amplification
in breast cancer patients. FISH for topoisomerase IIα (TOP2A) was also studied to see if deletion or amplifica-
tion of TOP2A has any supplementary role to HER-2, FISH and IHC.
Materials and Methods: Assessment of HER-2 gene amplification and TOP2A gene amplification/deletion was
made by FISH analysis using the LSI TOP2A/HER-2/CEP 17 multicolor probe or the LSI HER-2/CEP dual color
probe (Vysis, Downers Grove, IL, USA) in formalin-fixed and paraffin-embedded tissue sections of 54 breast
cancer patients who were grouped into stages 1+, 2+ or 3+ based on IHC (HercepTest; DakoCytomation,
Carpinteria, CA, USA) observations.
Results: None of IHC 1+ breast tumors was HER-2 FISH positive, but three of 18 (17%) IHC 3+ tumors were
HER-2 FISH negative. Overall, 53% of the IHC 2+ and 83% of the IHC 3+ cases were HER-2 FISH positive. Only
one case with IHC 3+ tumor that was HER-2 FISH positive was found to have TOP2A amplification (> 2.0) and
no IHC 2+ cases were found to have TOP2A amplification. There were no cases with TOP2A deletion (< 0.8) in
our whole series. There were also no cases of HER-2 FISH negative tumors, but IHC scored as 2+ or 3+ (0 of 10), to
be found with TOP2A amplification. The discordance rates by IHC were high (46.7% in IHC 2+, 16.7% in IHC
3+, 30.3% overall in IHC 2+ or 3+). On the contrary, the discordance rates were zero if by FISH.
Conclusion: The current algorithm to use HER-2 FISH as a supplementary role to IHC HercepTest 2+ may need
some modifications according to the local setting. TOP2A FISH adds little value to HER-2 FISH and IHC staining
in our study. [Taiwan J Obstet Gynecol 2007;46(2):146–151]
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breast cancer [1]. The overexpression of HER-2/neu is
associated with increased tumor growth rate, enhanced
metastatic rate, shorter disease-free survival, and over-
all survival. It is well-known that patients with HER-2/neu
(formerly known as c-erbB-2) overexpressing tumors
have a more aggressive and more malignant course than
patients without such overexpression, as seen in
Taiwanese breast cancer patients [2], a finding similar
to studies reported elsewhere [3].
Overexpression of HER-2/neu can be studied at 
the levels of DNA, mRNA and protein, using fluor-
escence in situ hybridization (FISH), Northern blot,
and Western blot and immunohistochemistry (IHC),
respectively. Amongst them, IHC and FISH are the two
most accessible and feasible methodologies used in
clinical diagnosis.
FISH analysis has enhanced the sensitivity of the stan-
dard karyotype and permitted the detection of sub-
microscopic abnormalities. With this new method,
targeted DNA sequences are visualized, permitting analy-
sis and quantification of disease at the molecular level. It
is more sensitive than standard cytogenetics since it can
survey many more cells at interphase. In the process of
FISH analysis, the probe is labeled with a fluorescent
dye. The probe binds to the chromosome in situ, and the
location of the hybridized fragment is revealed by a
bright fluorescent signal. FISH permits analysis of both
cell cultured materials and paraffin-embedded archival
tissues, the latter being particularly useful when used in
a clinical diagnostic setting.
HER-2/neu has been targeted by a variety of strate-
gies, including monoclonal antibodies, immunoconju-
gates and vaccines. A targeted immunotherapy, using
a humanized monoclonal antibody, trastuzumab (Her-
ceptin; Genentech, South San Francisco, CA, USA), was
devised to tackle breast carcinomas with overexpression
of HER-2/neu. The US Food and Drug Administration
(FDA) approved an immunohistochemical assay
(HercepTest; DakoCytomation, Carpinteria, CA, USA)
to assess the HER-2 status in formalin-fixed, paraffin-
embedded tissue of breast carcinoma in 1998. How-
ever, reports showed a false-positive rate ranging from
6% to more than 50% with the HercepTest. Therefore,
FISH test for HER-2 status was proposed [4,5].
However, despite the fact that most studies revealed
high concordance rates of HER-2 FISH when IHC is 0/1+
or 3+, a significant discordance was observed between
HER-2 FISH and IHC 2+ and between IHC 2+ and
mRNA data. Some authors even claimed to find a very
high discordance rate between HER-2 FISH and IHC 
in all four IHC scores (0, 1+, 2+, 3+), and a FISH-alone
screening strategy was alternatively suggested [6]. Mean-
while, a strategy to screen HER-2 status was developed
by some laboratories, and the strategy was that IHC
be used first to screen the specimens of breast cancer.
Expression of HER-2/neu protein was then scored as 0,
1+, 2+ or 3+. Herceptin was prescribed to patients whose
IHC for HER-2/neu was 3+. Those with a score of 2+
received an adjunct FISH analysis by using a probe aimed
at HER-2/neu (17q11.2–12) to see if there was an ampli-
fication of the HER-2/neu proto-oncogene. Herceptin
was given only in those if HER-2 FISH was positive for
amplification, even though the IHC score was only 2+.
There is still some controversy in the discordance rate
between IHC and FISH. Some studies revealed a high
discordance rate between FISH and IHC in all four IHC
scores (e.g. 92% discordance rate in the study by Dolan
and Snover [4]) [5], which contradicted with the conclu-
sion held by many investigators that a high discordance
rate might only exist in the IHC 2+ group [7]. Factors,
including the experience of the pathologists who per-
formed the IHC analysis, the standard of the cytoge-
netic laboratory, the method of obtaining specimens
(fine needle aspiration, biopsy, or surgical specimen)
and the composition of the patient population, may all
influence the interpretation of IHC and FISH analysis.
We wanted to perform our own analysis in our own local
setting to see the concordance and discordance rates
between the two tests (IHC and HER-2 FISH). Besides,
topoisomerase IIα (TOP2A) was noted to co-amplify
or was deleted in tumor tissue with HER-2 amplification.
We were also interested in seeing if TOP2A FISH was
helpful in amending the discordance of the two more
widely applied methodologies: IHC and HER-2 FISH,
and thereby reducing the risk and the cost of unneces-
sary exposure to Herceptin. A few other groups from
Taiwan have studied the related issues; one previous
study reported that overexpression of HER-2/neu cor-
related well to tumor staging, survival, and lymph node
metastasis, which was similar to the reports from other
parts of the world, apart from the finding that the 
percentage of HER-2/neu overexpression was higher 
in Taiwanese than in Caucasians [2]. Other groups
reported that overexpression of HER-2/neu protein is
common in both familial and non-familial breast cancers
and correlated well to the metastasis-free survival [8–10].
A similar study of a larger scale that was conducted at
the National Health Research Institute of Taiwan (NHRI)
targeted at studying the correlation between HER-2
FISH and IHC 2+ and recommended a similar strategy
of HER-2 screening in breast cancer patients, i.e. to use
IHC as a primary tool and HER-2 FISH as an adjunct
when the IHC score is 2+ [11]. We accumulated experi-
ence, during 2002 to 2005, as a single institute by close
collaboration with the cytogenetic laboratory and the
pathology department (both are one of the largest
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laboratories of its kind in central Taiwan) and were
keen to see whether our experience follows the trend
reported previously by other groups in Taiwan.
Materials and Methods
Samples
A total of 54 formalin-fixed, paraffin-embedded tissue
sections were retrieved from the tissue bank of our patho-
logy department. The record revealed that the specimens
belonged to 54 different patients with primary breast
cancer of different stages during 2003 to 2005 who
received excisional biopsy. The samples were then sent
to the pathologists and the cytogeneticists separately,
with both groups not knowing each other’s results until
the data were incorporated together for analysis.
Immunohistochemical analysis
Immunohistochemical study was performed on paraffin-
embedded, formalin-fixed tissue sections using the
HercepTest (DakoCytomation, Carpinteria, CA, USA)
following the manufacturer’s instructions. Briefly, this
procedure included the deparaffinization and rehydra-
tion steps, followed by an epitope retrieval step in
which the tissue sample was incubated in a citrate
buffer solution at 90–95°C for 20 minutes. The slide
was then subjected to a series of alternating washes in
tris(hydroxymethyl)aminomethane hydrochloride buffer
and incubation steps with, first, a peroxidase-blocking
reagent for 5 minutes and then with HER-2 primary anti-
body, followed by a visualization reagent (dextran poly-
mer conjugated with horseradish peroxidase and goat
anti-rabbit immunoglobulins) for 30 minutes each, and
finally with a 3,3′-diaminobenzidine chromogen solu-
tion. After a final wash, the slide was counterstained with
hematoxylin [4].
Scoring was performed according to the manufac-
turer’s recommendations by pathologists with at least
5 years of experience in clinical practice and was finally
reviewed by one of the coauthors (Yeh) who had partic-
ular experience in breast pathology and immunohisto-
chemical interpretation of HER-2 testing.
FISH analysis
HER-2 FISH was performed on formalin-fixed, paraffin-
embedded tissue specimens from each of the 54 patients
using the PathVysion kit (Vysis, Downers Grove, IL,
USA). Included in this kit are probes to the HER-2 gene
locus at 17q11.2–12 (labeled with SpectrumOrange)
and to the centromeric region of chromosome 17 (CEP
17; labeled with SpectrumGreen). TOP2A FISH was per-
formed on formalin-fixed, paraffin-embedded tissue
specimens from each of the 54 patients using the locus
specific identifier (LSI) TOP2A kit (Vysis, Downers
Grove, IL, USA). Included in this kit are probes to the
TOP2A gene locus at 17q21–22 that encodes topoiso-
merase II (labeled with SpectrumOrange) and to the
centromeric region of chromosome 17 (CEP 17; labeled
with SpectrumGreen). FISH analysis was performed
according to the manufacturer’s instructions (after
obtaining proficiency certification on completion of
training by Vysis), with minor modifications as described
subsequently. Our laboratory passed the accreditation
of cytogenetics and FISH testing by the College of
American Pathologists and by the supervising body in
our government (Department of Health, Taiwan).
Briefly, unstained 3- to 5-µm thick paraffin sections
were cut from blocks chosen by the referring patho-
logists and placed on positively charged slides. On
receipt, the slides were placed in an oven at 94°C for
approximately 5 hours, deparaffinized in xylene, and
dehydrated in a series of ethanol washes. After pretreat-
ment in 0.2 N hydrochloric acid and sodium thiocyanate
solutions, digestion in a protease solution for 16 minutes,
and fixation in 10% neutral buffered formalin, the slides
were subjected to denaturation and hybridization with
10 µL of the PathVysion probe/buffer mixture.
Fluorescence microscopy integrated with a cooled
CCD camera system and Smart Capture software
(CytoVision Chromophour System; Applied Imaging
Ltd., Carlsbad, CA, USA) for chromosome arrangement
was used to investigate and analyze the FISH results.
Scoring was performed according to the manufac-
turer’s recommendations by cytogenetic technologists
with at least 2 years of experience in clinical testing
and was finally reviewed by two of the coauthors
(Chen and Wang) who both had particular experience
in molecular cytogenetics.
Results
Of the 54 specimens in our study (25, invasive lobular
carcinoma; 29, invasive ductal carcinoma with varying
tumor grades and clinical stages), none was classified
as IHC 0, 21 were classified as IHC 1+, 15 were classi-
fied as IHC 2+, and 18 were classified as IHC 3+ by
HercepTest. None of the 21 IHC 1+ cases was found
to be HER-2 FISH positive (amplified Her-2/neu with a
Her-2/neu to CEP 17 ratio > 2.0 by counting at least
100 interphase nuclei; Figure 1), eight of the 15 IHC
2+ cases and 15 of the 18 IHC 3+ case were found to
be HER-2 FISH positive (Table 1). No statistical signifi-
cance between the tumor cell type and IHC status was
noted (data not shown).
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Discordance was defined as a discrepancy existing
between the IHC and HER-2 FISH, including the follow-
ing two conditions: (1) IHC 2+ or 3+ but HER-2 FISH
negative (a Her-2/neu to CEP 17 ratio < 2.0 by count-
ing at least 100 interphase nuclei); (2) IHC 1+ but HER-
2 FISH positive. The discordance rate according to
IHC 2+ was defined as the number of discrepant IHC 2+
cases divided by the total number of IHC 2+ cases and
was 46.7% (7/15). The discordance rate according to
IHC 3+ was defined as the number of discrepant IHC
3+ cases divided by the total number of IHC 3+ cases
and was 16.7% (3/18). The overall discordance rate by
IHC was therefore 30.3% (10/33). Following the same
way of counting, we easily found that the discordance
rates by FISH were 0 and 0 (Table 2).
Only one case with IHC 3+ and HER-2 FISH posi-
tive was found to have an amplified topoisomerase IIa
(TOP2A FISH positive). All the other 53 cases were
found to have a normal copy number of TOP2A (ratio,
0.8–2.0) with very good quality signals (Figure 2).
Remarkably, there was no failed hybridization in the
FISH analyses we performed in this study.
Discussion
Since the research regarding the role of Her-2/neu in
breast carcinogenesis led to the development of the
targeted immunotherapeutic monoclonal antibody tras-
tuzumab (Herceptin), diagnostic laboratory tests are
being investigated thoroughly to help detect the over-
expression of Her-2/neu in patients with breast cancer
with acceptable sensitivity and specificity suitable for
clinical use. The biological events underlying HER-2-
driven breast cancer that can be assessed in routine
clinical specimens include evaluation of gene amplifi-
cation by FISH, enhanced messenger RNA expression
by reverse transcription polymerase chain reaction and
Northern blotting, and the assessment of protein over-
expression at the tumor cell membrane by IHC. The US
Figure 1. Marked amplification of human epidermal growth
factor receptor-2/neu (Her-2/neu) gene locus was noted. The
ratio of Her-2/neu (red signals) to CEP 17 (green signals) is
obviously larger than 2.0.
Table 1. Results of HercepTest—immunohistochemistry (IHC), human epidermal growth factor receptor-2 (HER-2)—
fluorescence in situ hybridization (FISH), and topoisomerase IIα (TOP2A)—FISH
Distribution of Distribution of Distribution of
IHC scoring
Number of HER-2 FISH amplified TOP2A FISH amplified TOP2A-FISH deleted
patients (> 2.0 and denotes (> 2.0 and denotes (< 0.8 and denotes 
amplified HER-2/neu gene) amplified TOP2A gene) deleted TOP2A gene)
1+ 21 0 0 0
2+ 15 8 0 0
3+ 18 15 1 0
Table 2. Concordance between HercepTest and human epidermal growth factor receptor-2 (HER-2)—fluorescence in situ
hybridization (FISH) results
HercepTest
HER-2 FISH HER-2 FISH Concordance by IHC Discordance by IHC
amplified non-amplified score (%) score (%)
1+ (n = 21) 0 21 100 0
2+ (n = 15) 8 7 53.3 46.7
3+ (n = 18) 15 3 83.3 16.7
Concordance by FISH score (%) 100 100 — —
Discordance by FISH score (%) 0 0 — —
IHC = immunohistochemistry.
Taiwan J Obstet Gynecol • June 2007 • Vol 46 • No 2150
S.J. Kuo, et al
FDA approved the immunohistochemical test
HercepTest in 1998 and the FISH test Her-2 FISH
pharmDx™ Kit (DakoCytomation, Carpinteria, CA,
USA) in 2005 to mark the fact that IHC study to detect
Her-2/neu protein overexpression and FISH to detect an
increase in gene copy number of Her-2/neu locus are the
two mainstream diagnostic tests of choice in the daily
clinical practice.
We did not intend to compare the sensitivity and
specificity of these two tests, since a great number of
extensive studies had been published [12–14]. Besides,
the case number in our study (n = 54) was also not
that large for us to draw any meaningful statistical cor-
relation between the two tests and the clinical parame-
ters such as tumor staging, grading, cell types, the
status of nodal involvement, and patient survivals.
Many previous studies in Taiwan had demonstrated
the role of Her-2/neu overexpression in breast carcino-
genesis in Taiwanese, and the data were comparable
to those reported elsewhere in the world [2,8–10].
This study wishes to answer a simple question: what
are the concordance and discordance rates between
IHC and HER-2 FISH in our own setting, and is TOP2A
FISH helpful to the discordant cases? A similar study
reported by Dolan and Snover [4] adopted a similar
strategy, but they represented a report from a referral lab-
oratory that receives samples referred from many surgical
departments, which is different from us and the samples
in their study might be of a more heterogeneous nature
than those in our study. Another study from our NHRI
also represented a core FISH laboratory that receives
samples referred from a number of hospitals across the
country [11]. Many factors such as a greater variability
in the quality of sample preparation from many pathol-
ogy departments and a greater interpersonal variability,
thus, may cloud the result of those studies, despite that
the conditions in those two studies actually also reflect
part of the true condition encountered in the daily clini-
cal practice. Our study, therefore, wishes to answer the
question in a much simpler and less clouded setting 
and also reflects our own real condition in clinical rou-
tine practice. Considerably high discordance rates in our
study (46.7% in IHC 2+ and 16.7% in IHC 3+) and in 
a previous study from the US (86% in IHC 2+ and 54%
in IHC 3+) imply the inherent differences in sensitivity
and specificity of these two testing methods. Moreover,
the quality of sample preparation also affects the per-
formance of these two tests. Result of FISH analysis is
easily jeopardized by poor preparation (too thickly
sectioned, unsatisfactory deparaffination, tissue dam-
age). However, poor quality is more dangerous in IHC
results, because it will lead to a wrong assignment of
the samples to “negative” result [15]. Fortunately, we
did not have any IHC 0 cases included in our study and
the influence of such a factor would be lessened. 
A French multi-centered study, using FISH as a gold
standard, also revealed that IHC scoring in HER-2-status
needs a more standardized cut-off level (e.g. more than
60% stained cells were classified as overexpression) to
improve its concordance with FISH, implying the fact
that IHC scoring is somewhat subjective and prone to
interpersonal variation [16].
Theoretically, to use a FISH-alone strategy in breast
cancer patients with Her-2/neu overexpression may miss
those who have overexpression of Her-2/neu at protein
level but do not have copy number change at DNA level,
the prevalence of which is approximately 3% [12].
Whether we can change our algorithm to FISH alone,
since now our data revealed the discordance by FISH is
zero, awaits further study; while at least in our hospital
with a sound FISH laboratory, change in algorithm may
be a reasonable alternative and must be examined by
correlating with the clinical parameters in the future.
Meanwhile, in order to solve the discrepancy between
the HER-2 FISH and HercepTest IHC, the role of topo-
isomerase IIa was studied. The study from our NHRI
reported that the topoisomerase IIa gene was co-amplified
in 21% and was deleted in 15% of HER-2/neu amplified
samples, which implies that amplification or deletion
of topoisomerase II gene may have some supplementary
value in the diagnosis of breast cancers with overex-
pression of HER-2/neu. On the contrary, a study coau-
thored by Hicks et al [17] indicated that TOP2A was
Figure 2. Topoisomerase IIα (TOP2A) fluorescence in situ
hybridization (FISH) revealed a normal pattern of topoiso-
merase II (red signals) when compared with the internal con-
trol aimed at centromere 17 (green signals).
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never amplified in the absence of HER-2 amplification
and was co-amplified in 50% of HER-2 amplification
cases; HER-2 gene copy number was higher than the
TOP2A copy number (p < 0.01). However, in our study
series, TOP2A was only co-amplified in 6% of IHC3+
cases. We also did not observe any deletion cases in
TOP2A FISH. Our study revealed that TOP2A FISH has
little value to be an adjunct test to the current algo-
rithm. We, therefore, have aborted the TOP2A FISH for
such use in our hospital since 2006.
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